A straightforward meta‐analysis approach for oncology phase I dose‐finding studies - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles Statistics in Medicine Year : 2022

A straightforward meta‐analysis approach for oncology phase I dose‐finding studies

Abstract

Phase I early-phase clinical studies aim at investigating the safety and the under-lying dose-toxicity relationship of a drug or combination. While little may still be known about the compound’s properties, it is crucial to consider quantitative infor-mation available from any studies that may have been conducted previously on the same drug. A meta-analytic approach has the advantages of being able to properly account for between-study heterogeneity, and it may be readily extended to prediction or shrinkage applications. Here we propose a simple and robust two-stage approach for the estimation of maximum tolerated dose(s) (MTDs) utilizing penalized logistic regression and Bayesian random-effects meta-analysis methodology. Implementa-tion is facilitated using standard R packages. The properties of the proposed methods are investigated in Monte-Carlo simulations. The investigations are motivated and illustrated by two examples from oncology.
Fichier principal
Vignette du fichier
2110.06132 (347.62 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-03864767 , version 1 (11-12-2023)

Licence

Identifiers

Cite

Christian Röver, Moreno Ursino, Tim Friede, Sarah Zohar. A straightforward meta‐analysis approach for oncology phase I dose‐finding studies. Statistics in Medicine, 2022, 41 (20), pp.3915-3940. ⟨10.1002/sim.9484⟩. ⟨hal-03864767⟩
31 View
2 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More